Research and preclinical stage
All work described publicly is at a research or preclinical stage. We do not describe clinical activity, approved products or regulatory outcomes.
Company
About exRNA Therapeutics
Founded in 2021, exRNA Therapeutics is a research-led biotechnology company operating from Bodh Gaya, Bihar. Our work spans nucleic-acid structure, oligonucleotide systems and microbial biology, supported by computational, molecular, cell-based and preclinical research capabilities.
Our research
Our work spans three connected areas: nucleic-acid structure and higher-order organization, oligonucleotide systems, and beneficial microbial biology. Each is described at a conceptual level on our science page.
That research is supported by computational, molecular, cell-based and preclinical capabilities, together with the research records that accompany them. All work is at a research or preclinical stage.
Responsible scientific communication
We hold ourselves to a written standard for what may be said publicly about our research. It rules out therapeutic, comparative and outcome claims, and keeps research-stage detail — molecular designs, materials, methods and results — outside our public materials.
That standard is published in this website's source rather than kept internal, so anyone can see the basis on which these pages are written.
Founded
2021
Operating from
Hathiyar, Bodh Gaya, Gaya, Bihar 824231, India
Research areas
Nucleic-acid structure, oligonucleotide systems and microbial biology
Stage
Research and preclinical
Enquiries
Research principles
How we describe our work
No therapeutic or comparative claims
Our public materials make no claim of therapeutic benefit, no comparison to any other approach or product, and no assertion about outcomes.
Deliberate disclosure
We describe our areas of research at a high level. Research-stage detail — including molecular designs, materials, methods and results — is not published.
Careful language
We aim to be precise about what is established and what is not. Where a question is unresolved, we describe it as unresolved.
Contact
Talk to the company
For general, research or partnership enquiries, write to us directly.